HKU Scholars Hub: Browsing DSpace

Browsing by Author Tseng, LM

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 3 to 6 of 6 < previous

	Title	Author(s)	Issue Date	Views
	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Journal:Lancet	Baselga, J Bradbury, I Eidtmann, H Di Cosimo, S de Azambuja, E Aura, C Gomez, H Dinh, P Fauria, K Van Dooren, V Aktan, G Goldhirsch, A Chang, TW Horvath, Z Coccia-Portugal, M Domont, J Tseng, LM Kunz, G Sohn, JH Semiglazov, V Lerzo, G Palacova, M Probachai, V Pusztai, L Untch, M Gelber, RD Piccart-Gebhart, M NeoALTTO Study Team,Kwong, A	2012	124
	LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatinib (L) Proceeding/Conference:Journal of Clinical Oncology	Hickish, T Tseng, LM Mehta, AO Tsang, J Kovalenko, N Udovitsa, D Pelling, K Uttenreuther-Fischer, MM Huang, CS LUX-Breast 2 Study Group	2012	44
	Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study Journal:Japanese Journal of Clinical Oncology	Shao, Z Tseng, LM Huang, CS Pang, D Yang, Y Li, W Liao, N Geng, C Zhang, Q Xu, B Liu, D Kwong, A	2021	1
	Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study Journal:Breast Cancer Research and Treatment	Huang, CS Yang, Y Kwong, A Chen, SC Tseng, LM Liu, MC Shen, K Wang, S Ng, TY Feng, Y Sun, G Yan, IR Shao, Z	2021	16

Showing results 3 to 6 of 6 < previous